NCT03489837已完成3 期
A Randomized, Double-blind, Multicenter, Active-controlled Phase III Study to Evaluate the Efficacy and Safety of Levotuss CR Tab. in Comparison With Levotuss Syrup in Patients With Cough Due to Acute or Chronic Bronchitis
Hyundai Pharm1 个研究点 分布在 1 个国家目标入组 272 人开始时间: 2017年1月最近更新:
适应症
干预措施
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 272
- 试验地点
- 1
- 主要终点
- Cough severity check
研究概览
简要总结
A randomized, double-blind, multicenter, active-controlled phase III study to evaluate the efficacy and safety of Levotuss CR tab. in comparison with Levotuss syrup in patients with cough due to acute or chronic bronchitis
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Care Provider)
入排标准
- 年龄范围
- 19 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •moderate, severe, very severe non-productive cough patients
排除标准
- •Patients receiving a concomitant therapy
研究组 & 干预措施
Levotuss CR tab
Experimental
oral taken
干预措施: Levotuss (Drug)
Levotuss syrup
Active Comparator
oral taken
干预措施: Levotuss (Drug)
结局指标
主要结局
Cough severity check
时间窗: 6 hours
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
A Study to Evaluate the Effiacy and Safety of HIP0612 in Patients with Gastric UlcerGastric UlcerNCT05656092Hanmi Pharmaceutical Company Limited199
招募中
3 期
A Phase III Study of Oral Sudapyridine (WX-081) Tablets in Rifampicin-Resistant Pulmonary Tuberculosis PatientsRifampin-Resistant Pulmonary TuberculosisTuberculosis, Multidrug-Resistant (MDR-TB)NCT05824871Shanghai Jiatan Pharmatech Co., Ltd450
Unknown
3 期
BPDO-1603 Intervention Trial in Patients With Moderate-to-severe Alzheimer's DiseaseModerate-to-severe Alzheimer's DiseaseNCT04229927Hyundai Pharmaceutical Co., LTD.712
已完成
3 期
Phase III Clinical Trial of DP-R206 and Bonvia In Postmenopausal Women With OsteoporosisPostmenopausal Women With OsteoporosisNCT01581320Alvogen Korea201
已完成
3 期
Efficacy and Safety of CKDB-501A in Subjects With Moderate-to-severe Glabellar Lines in Phase 3 TrialGlabellar LinesNCT05804656CKD Bio Corporation300